Corcept Therapeutics (CORT) Cash from Financing Activities (2010 - 2026)

Corcept Therapeutics has reported Cash from Financing Activities for 17 years, with the latest figure at -$2.0 million in Q2 2026.

• Quarterly Cash from Financing Activities rose 98.02% year-over-year to -$2.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$78.9 million (up 53.14% YoY) and the FY2025 annual result came in at -$220.4 million, down 677.33% from the prior year.
• Cash from Financing Activities retreated to -$2.0 million in Q2 2026 per CORT's latest filing, from $760000.0 in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $766000.0 in Q4 2023 and troughed at -$145.8 million in Q2 2023.
• A 5-year average of -$23.1 million and a median of -$3.3 million in 2022 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2023 and 2025: Cash from Financing Activities jumped 1355.74% in 2023, then plunged 7230.2% in 2025.
• Over 5 years, Cash from Financing Activities stood at -$61000.0 in 2022, then surged by 1355.74% to $766000.0 in 2023, then plunged by 695.82% to -$4.6 million in 2024, then slumped by 583.96% to -$31.2 million in 2025, then surged by 93.47% to -$2.0 million in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered -$2.0 million, $760000.0, and -$31.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.